Phaseline

Companies › Protara Therapeutics

Protara Therapeutics: clinical trials, targets and expected readouts

2 active drug programs in 4 registered trials: 3 Phase 2, 1 Phase 3; Metabolic and endocrine, Oncology, Other; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
TARA-002–Phase 3Bladder (Urothelial, Transitional Cell) Cancer; Lymphatic Malformation; Non-muscle Invasive Bladder CancerDec 2026
Choline Chloride for Injection
Essential nutrient and choline precursor for phosphatidylcholine synthesis
–Phase 2Choline DeficiencyMar 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05871970TARA-002Phase 2Lymphatic MalformationOtherDec 2026
NCT06910943Choline Chloride for InjectionPhase 2Choline DeficiencyMetabolic and endocrineMar 2028
NCT07480356TARA-002Phase 3Bladder (Urothelial, Transitional Cell) CancerOncologyApr 2028
NCT05951179TARA-002Phase 2Non-muscle Invasive Bladder CancerOncologyOct 2031

From the company's SEC filings

Cash and short-term investments of $127m on 2026-09-30; operating cash outflow about $74m a year; runway about 21 months at that burn, to Jun 2028; 3 of 4 coming phase 2-3 readouts fall inside that runway

Press releases filed as 8-K in the last year:

Specialist investors

Held by 4 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Energenesis Biomedical Relay Therapeutics HTA J-Pharma Kailera

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.